Compare Flux Power Holdings Inc (FLUX) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Incyte Corporation — how do they compare? Flux Power Holdings Inc trades at $0.6 (market cap $11.23M), while Incyte Corporation trades at $120.77 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 2185.2× Flux Power Holdings Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.
| FLUX | INCY | |
|---|---|---|
Market Cap | $11.23M | $24.54B |
Sector | Utilities | Health |
52-Week High | $6.66 | $129.93 |
52-Week Low | $0.51 | $81.61 |
Enterprise Value | $17.39M | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX stock surged 17.58% to $0.6161, showing strong daily momentum despite a bearish technical backdrop with 17 sell signals. The company reported mixed quarterly earnings, missing estimates in Q3 2025 and Q1 2026 but beating in Q4 2025. Revenue declined to $51M in 2026 from $66M in 2025, with a net income margin of -12.48%. Recent developments include the launch of SkyEMS 3.0 AI platform and a new VP of Sales appointment, aiming to bolster growth in the energy storage sector.
Outlook is cautiously optimistic due to unanimous analyst buy ratings but tempered by profitability challenges and technical weakness. Key opportunities lie in AI-driven fleet solutions expansion, while risks include persistent losses, competitive pressure, and execution hurdles in scaling operations.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
